Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress Replay
ESMO 2018 Key CIT readouts across tumor types
Roche Oncology strategy update
Daniel O’Day, CEO Roche Pharmaceuticals
IMpassion130: Tecentriq + Abraxane in 1L triple-negative breast cancer
IMpower130: Tecentriq + Abraxane in 1L non-sq NSCLC
Jakob Dupont, M.D., Global Head Breast & Gyn Cancer Franchise, Pharma Development
BF1RST: Association between bTMB and Tecentriq efficacy in 1L NSCLC ALESIA: Alecensa in 1L ALK+ NSCLC in Asian patients STARTRK2: Entrectinib in NTRK+ solid tumors GO30140: Tecentriq + Avastin in 1L HCC Alan Sandler, M.D., Global Head of Lung/Head & Neck Franchise, Pharma Development, a.i. Global Head Oncology

Please register to access the replay*

*Privacy notice

Roche has hosted a live audio webcast and conference call on Monday, 22 October 2018.

Past IR Events
View more Events


Related links